Interferon β variants and conjugates

Details Interferon β variants and conjugates Interferon β variants and conjugates

2006-12-05

2006-12-05

Saoud, Christine J. (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C424S085400, C514S012200, C530S350000, C530S351000, C530S395000, C530S397000

Reexamination Certificate

active

07144574

ABSTRACT:
The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4686191 (1987-08-01), Itoh et al.
patent: 4769233 (1988-09-01), Bell et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4914033 (1990-04-01), Bell et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 4966843 (1990-10-01), McCormick et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5218092 (1993-06-01), Sasaki et al.
patent: 5376567 (1994-12-01), McCormick et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5545723 (1996-08-01), Goelz et al.
patent: 5738846 (1998-04-01), Greenwald et al.
patent: 5795779 (1998-08-01), McCormick et al.
patent: 6531122 (2003-03-01), Pedersen et al.
patent: 083 069 (1987-09-01), None
patent: 0 287 075 (1988-10-01), None
patent: 0 370 205 (1990-05-01), None
patent: 041 313 (1990-09-01), None
patent: 229 108 (1990-12-01), None
patent: 260 350 (1992-02-01), None
patent: 0 529 300 (1993-03-01), None
patent: 287 075 (1995-01-01), None
patent: 539 300 (1996-02-01), None
patent: 593 868 (1998-04-01), None
patent: WO 95/25170 (1995-09-01), None
patent: WO 95/27502 (1995-10-01), None
patent: WO 98/35026 (1998-08-01), None
patent: WO 98/48018 (1998-10-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/55377 (1999-11-01), None
patent: WO 99/55377 (1999-11-01), None
patent: WO 99/67291 (1999-12-01), None
patent: WO 00/23114 (2000-04-01), None
patent: WO 00/23472 (2000-04-01), None
patent: WO 00/26354 (2000-05-01), None
patent: WO 01/15736 (2001-03-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Wells, Aditivity of Mutational Effects in Proteins, 1990, Biochemistry, vol. 26, No. 37, pp. 8509-8517.
Apweiler et al. On the frequency of protein glycosylation, as deducted from analysis of the SWISS-PROT database (1999). BBA 1473 pp. 4-8.
O'Connell, et al., “The Influence of Flanking Sequences on O-Glycosylation”,Biochemical and Biophysical Research Communications, 1991, pp. 1024-1030, 180:2.
Fierlbeck et al., “Neutralising interferon β antibodies in melanoma patients treated with recombinant and natural interferon β ”Cancer Immunol Immunother(1994) 39:263-268.
Karpusas et al., “The Structure of Human Interferon- β: Implications for activity”CMLS54 (1998) 1203-1216.
Karpusas et al. “The crystal structure of human interferon β at 2.2 A resolution” Proc. Nat. Acad. Sci. USA (1997) 94:11813-11818.
Mayorga et al., “Antibodies to Commercially Available Interferon-Bet Molecules in Multipule Sclerosis Patients Treated with Natural Interferon-Beta”Int. Arch. Allery Immunol1999; 118:368-371.
Munschauer et al., “Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis”Clinical Therapeuticsvol. 19, No. 5, 1997 883-893.
Redlich et al., “Antibodies that neutralize human β interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping”Proc. Natl. Acad. Sci. USAvol. 88, pp. 4040-4044 May 1991.
Rudick et al., “Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis”NeurologyMay 1889, 50: 1266-1272.
Runkel et al., Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β)Pharmaceutical Researchvol. 15, No. 4, 1998, 641-649.
Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between α and β Type 1 Interferons Explored by Mutational Analysis 273, No. 14, pp. 8003-8008.
Senda et al., “Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution”J. Mil. Biol. (1995) 253, 187-207.
Stewart et al, DNA Chemical Mutagenesis of Human Interferon- β: Construction, Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations vol. 6 No. 2 1987 p. 119-128.
Tanigunchi, et al., “The nucleotide sequence of human fibroblast interferon cDNA”Gene10 (1980) 11-15.
Yong et al., “Interferon beta in the treatment of multiple sclerosis”Neurology1998; 51: 682-689.

Affiliated with

Also associated with

Rating

Interferon β variants and conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Interferon β variants and conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon β variants and conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3673470